# SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer

> **NCT04977024** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **GeoVax, Inc.** · enrollment: 63 (actual)

## Conditions studied

- COVID-19 Infection
- Hematopoietic and Lymphoid System Neoplasm
- Leukemia
- Lymphoma
- Plasma Cell Myeloma

## Interventions

- **BIOLOGICAL:** COVID-19 Vaccine
- **OTHER:** Diagnostic Laboratory Biomarker Analysis
- **BIOLOGICAL:** Synthetic MVA-based SARS-CoV-2 Vaccine GEO-CM04S1

## Key facts

- **NCT ID:** NCT04977024
- **Lead sponsor:** GeoVax, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-09-27
- **Primary completion:** 2026-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 63 (ACTUAL)
- **Last updated:** 2026-02-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04977024

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04977024, "SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04977024. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*